The recent Diaceutics report highlights a concerning issue in precision medicine: despite advancements in biomarker testing, a staggering 65% of eligible lung cancer patients still don't receive the most appropriate targeted therapies. This isn't just a testing problem anymore; it's a translation problem. The gap between testing and treatment decision-making has widened, with a 12% increase in patient loss at the treatment decision stage. This shift underscores the growing complexity and time pressure faced by clinicians, who often make treatment plans before full biomarker results are available. Only 43% consistently wait for these results, and over half don't consistently act on biomarker recommendations. This disconnect between expanding diagnostic capabilities and treatment decision-making is a critical issue that needs to be addressed. The industry must develop and adopt operating models that are diagnostic-enabled, data-driven, and continuously adaptive to optimize the patient journey. This requires a systemic approach that rebalances the focus towards treatment decision-making, improves consistency in biomarker test ordering, and provides real-time, actionable support to physicians at the point of care. The implications of this report are far-reaching, highlighting the need for a comprehensive reevaluation of precision medicine practices to ensure that patients receive the most appropriate treatments.
